These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19936766)

  • 1. K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer.
    Schimanski CC; Zimmermann T; Schmidtmann I; Gockel I; Lang H; Galle PR; Moehler M; Berger MR
    Int J Colorectal Dis; 2010 Feb; 25(2):181-6. PubMed ID: 19936766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer.
    Gockel I; Moehler M; Frerichs K; Drescher D; Trinh TT; Duenschede F; Borschitz T; Schimanski K; Biesterfeld S; Herzer K; Galle PR; Lang H; Junginger T; Schimanski CC
    Oncol Rep; 2008 Oct; 20(4):845-50. PubMed ID: 18813825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer.
    Schimanski CC; Moehler M; Gockel I; Zimmermann T; Lang H; Galle PR; Berger MR
    J Cancer Res Clin Oncol; 2011 Jul; 137(7):1139-45. PubMed ID: 21468700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia.
    Zahrani A; Kandil M; Badar T; Abdelsalam M; Al-Faiar A; Ismail A
    Tumori; 2014; 100(1):75-9. PubMed ID: 24675495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does expression of receptor tyrosine kinases in gastric adenocarcinoma correlate with clinicopathological parameters?
    Drescher D; Gockel I; Timm S; Berger MR; Herzer K; Schmidtmann I; Junginger T; Galle PR; Lang H; Moehler M; Schimanski CC
    Hepatogastroenterology; 2010; 57(98):388-94. PubMed ID: 20583450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
    J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulated PDGFR alpha expression and novel somatic mutations in colorectal cancer: association to RAS wild type status and tumor size.
    Ben Jemii N; Tounsi-Kettiti H; Yaiche H; Mezghanni N; Jaballah Gabteni A; Fehri E; Ben Fayala C; Abdelhak S; Boubaker S
    J Transl Med; 2020 Nov; 18(1):440. PubMed ID: 33213472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of annexin A1 is correlated with K-ras mutation in colorectal cancer.
    Su N; Xu XY; Chen H; Gao WC; Ruan CP; Wang Q; Sun YP
    Tohoku J Exp Med; 2010 Dec; 222(4):243-50. PubMed ID: 21127395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.
    Nasir A; Reising LO; Nedderman DM; Fulford AD; Uhlik MT; Benjamin LE; Schade AE; Holzer TR
    Anticancer Res; 2016 Jun; 36(6):2683-96. PubMed ID: 27272777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis.
    Rao B; Gao Y; Huang J; Gao X; Fu X; Huang M; Yao J; Wang J; Li W; Zhang J; Liu H; Wang L; Wang J
    Int J Colorectal Dis; 2011 May; 26(5):593-601. PubMed ID: 21404058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
    Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.
    Kawamata H; Yamashita K; Kojo K; Ushiku H; Ooki A; Watanabe M
    Genomics; 2015 Aug; 106(2):71-5. PubMed ID: 26026309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
    Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
    BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.
    Pérez-Ruiz E; Rueda A; Pereda T; Alcaide J; Bautista D; Rivas-Ruiz F; Villatoro R; Pérez D; Redondo M
    Tumour Biol; 2012 Dec; 33(6):1829-35. PubMed ID: 22791568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copy number alterations of chromosomal regions enclosing protein tyrosine phosphatase receptor-like genes in colorectal cancer.
    Laczmanska I; Karpinski P; Kozlowska J; Bebenek M; Ramsey D; Sedziak T; Ziolkowski P; Sasiadek MM
    Pathol Res Pract; 2014 Dec; 210(12):893-6. PubMed ID: 25169130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency and spectrum of K-ras mutations among Iraqi patients with sporadic colorectal carcinoma.
    Al-Allawi NA; Ismaeel AT; Ahmed NY; Merza NS
    Indian J Cancer; 2012; 49(1):163-8. PubMed ID: 22842183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.